Humedics Invests in Ensolbio Shares to Strengthen Osteoarthritis Treatment Business

Targeting the Osteoarthritis Treatment Market

[Asia Economy Reporter Myunghwan Lee] Humedix announced on the 20th that it has signed a strategic equity investment agreement worth 5 billion KRW to strengthen business cooperation with Ensol BioScience.

Through this investment, Humedix secured a 5.08% stake in Ensol BioScience. Humedix explained that this equity investment was made based on the judgment that Ensol BioScience has strong technology, potential, and market competitiveness in peptide-based new drug development.

At the strategic equity investment contract ceremony between HuMedics and Ensol Biosciences held at the Huons Group headquarters in Pangyo, Seongnam, Gyeonggi Province, Jinwhan Kim, CEO of HuMedics (left), and Haejin Kim, CEO of Ensol Biosciences, are posing for a commemorative photo.
[Photo by HuMedics]

Ensol BioScience is developing new drugs such as treatments for degenerative disc disease, osteoarthritis, and anticancer agents based on peptide substances. Peptides are polymers composed of amino acid monomers, which regulate protein-protein interactions and are biocompatible substances that minimize side effects. Ensol BioScience possesses core technologies that shorten the discovery period of new drug candidates and maximize clinical success rates by utilizing its proprietary peptide candidate discovery platform and molecular interaction analysis system.

The main pipeline, osteoarthritis treatment E1K (Engedi1000), is currently conducting a Phase 1b clinical trial for DMOAD (disease-modifying osteoarthritis drug for cartilage regeneration) and a Phase 2 clinical trial for pain treatment simultaneously. Humedix explained that the results of the DMOAD Phase 1b clinical trial are expected to be available in the first half of this year.

With this investment, Humedix secured the priority negotiation rights for domestic commercialization of the osteoarthritis treatment E1K. Ensol BioScience plans to focus on new drug development and commercialization, including the osteoarthritis treatment E1K, using the investment funds.

Jinhwan Kim, CEO of Humedix, said, "Recently, Ensol BioScience passed the technical evaluation for KOSDAQ transfer listing and even has commercialized treatments, attracting attention from global pharmaceutical companies," adding, "Through this agreement, we plan to strengthen the cooperative system by combining the technologies and capabilities of both companies."

This content was produced with the assistance of AI translation services.